Paper

0

Document

Download

Flag content

0

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Show More

Authors

Andrzej Jakubowiak,Massimo Offidani

Brigitte Pegourié,Javier Rubia,Laurent Garderet,Kamel Laribi,Alberto Bosi,Roberto Marasca,Jacob Laubach,Ann Mohrbacher,Angelo Carella,Anil Singhal,L. Tsao,Mark Lynch,Eric Bleickardt,Ying‐Ming Jou,Michael Robbins

+15 authors

,Antonio Palumbo

Journal

Published

Apr 18, 2016

DOI

10.1182/blood-2016-01-694604

Show more

Save

Tip

Document

Download

Flag content

0

Tip

Save

Document

Download

Flag content

Abstract

Paper PDF

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.